Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-Guided Ruxolitinib for Prevention of Chronic GVHD After Allogeneic HCT
NCT07025538Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Apr 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ruxolitinib in graft-versus-host disease (GVHD) (2 arms), sponsored by City of Hope. Primary endpoints: Incidence of unacceptable toxicity at 28 days, Chronic graft versus host disease at 1 year and 3 more. Started Apr 2026; status: recruiting.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07025538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07025538.